I think you are on the money there. Devices aren't as sexy as drug trials generally so device business model is more of the long game. It is still attractive as a business because it provides access to top hospitals in oncology and that can't be discounted down the track.
Ann: OncoSil achieves first commercial sale, page-32
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.19M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.3¢ | $9.782K | 752.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 11636360 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 4307472 | 9 |
View Market Depth
| Last trade - 14.13pm 02/10/2024 (20 minute delay) ? |
| OSL (ASX) Chart |